General Assembly Raised Bill No. 5225 seeks to prohibit certain licensees and registrants from selling, dispensing, transferring, or delivering any drug or device intended for the execution of a death sentence. The bill amends Section 21a-70 of the general statutes, which will be repealed and replaced with new language effective October 1, 2026. Key definitions are clarified, including terms such as "commissioner," "drug," "manufacturer," and "person," with the term "wholesaler or manufacturer" being deleted and replaced with "person" to broaden the scope of those affected. The bill mandates that no person may operate as a manufacturer or wholesaler without a certificate of registration from the Commissioner of Consumer Protection, which must be renewed annually, although certain federally registered manufacturers outside Connecticut are exempt from this requirement.

Additionally, the bill introduces several regulatory measures aimed at enhancing the oversight of drug wholesalers and manufacturers. It explicitly prohibits these entities from selling drugs with the knowledge that the purchaser intends to use them for capital punishment and requires applicants to submit a signed statement affirming this commitment. The bill also establishes a fee structure for certificates, mandates reporting of suspicious orders, and clarifies that licensed pharmacists cannot dispense drugs intended for execution. Furthermore, it sets stricter guidelines for sterile compounding pharmacies, including notification requirements for remodeling and repairs, and prohibits them from providing pharmaceuticals for capital punishment. Overall, Raised Bill No. 5225 aims to strengthen ethical standards and safety protocols within the pharmacy practice while aligning with broader considerations surrounding capital punishment.

Statutes affected:
Raised Bill: 20-613a